Pexacerfont

Drug Profile

Pexacerfont

Alternative Names: BMS-562086

Latest Information Update: 04 Jun 2010

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antidepressants; Anxiolytics; Pyrazoles; Small molecules
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Generalised anxiety disorder; Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 22 May 2008 Efficacy data from a phase II trial in irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008)
  • 15 Jan 2008 Pexacerfont is still in phase II trials for Irritable bowel syndrome in the US
  • 31 Jul 2005 Phase-I/II clinical trials in Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top